US FDA to review Mylan's ANDA for Copaxone
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Mylan Laboratories' ANDA referencing Teva Pharmaceutical Industries' multiple sclerosis agent Copaxone (glatiramer acetate injection). The brand product has annual US sales exceeding $1 billion, and there is currently no approved generic formulation.